Pembrolizumab

elsewhere's corpus does not cover Pembrolizumab as a subject. The only retrieved material mentioning it is a 2021 Gaorong Ventures portfolio update that lists it in passing among other companies' drug development milestones, with no substantive information about what Pembrolizumab is, who developed it, or its clinical profile. The entity cards identify it as a product (with its Chinese name 帕博利珠单抗), but the bundle contains no sourced facts about its properties, indications, or manufacturer.